Detailed Information on Publication Record
2018
Heart failure and inhibition of renin-angiotensin-aldosterone system
VÍTOVEC, Jiří, Jindřich ŠPINAR and Lenka ŠPINAROVÁBasic information
Original name
Heart failure and inhibition of renin-angiotensin-aldosterone system
Authors
VÍTOVEC, Jiří (203 Czech Republic, guarantor, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution) and Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution)
Edition
Cor et Vasa, Amsterdam, Elsevier Science INC, 2018, 0010-8650
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/18:00103230
Organization unit
Faculty of Medicine
UT WoS
000433252900008
Keywords in English
Chronic heart failure; ACE inhibitors; Angiotensin receptor blockers; Mineralocorticoid receptor; antagonists; Aliskiren; Omapatrilat; Sacubitril/valsartan (LCZ 696)
Tags
International impact, Reviewed
Změněno: 10/2/2019 13:23, Soňa Böhmová
Abstract
V originále
A historical survey is presented of mortality clinical trials focussed on the inhibition of the renin-angiotensin-aldosterone system on different levels in patients with chronic heart failure. The first study, CONSENSUS, was published in 1987 and showed that the ACE-inhibitor enalapril clearly reduced mortality in severe heart failure compared with placebo. This was followed by studies with beta blockers, angiotensin II type 1 receptor blockers, blockers of mineralocorticoid receptors, and direct renin inhibitors. A recent study, PARADIGM, comparing dual inhibitor of neprilysin and antiotensin II receptor (LCZ 696) with enalapril, was terminated prematurely for a significant effect of inhibiting neprilysin and valsartan. (C) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.